Recolony focuses on the development of cancer therapies based on microbial-derived products. These drugs have an enormous influence on our immune system, enhancing an immune reaction against cancer. With this approach, Recolony will develop a new class of drugs for the treatment of cancer.

Products, services, technology

RCLBP01: Live Biotherapeutic Product for the treatment of colorectal cancer and other types of solid tumors.
RCLM01: Microbial-derived metabolite for the treatment of solid tumors.
RCLB01: Biomarker for early detection of CRC and therapy efficacy

Additional address info
  • F Floor
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business

You may also be interested in